Non-invasive Assessment of Mechano-chemical Properties of Urine Proteins by Hybrid Brillouin-Raman Spectroscopy

Nazarbayev University

Status: Active, not recruiting

Conditions: Nephrotic Syndrome

Treatments: Device: hybrid Brillouin-Raman spectroscopy

Study type: Observational

Funder types: Other

Identifiers

NCT04311684

091019CRP2105

Details and patient eligibility

About

The proteinuria is widely recognized as a marker of kidney disease severity, as well as the predictor of renal function decline, cardiovascular outcomes, and all-cause mortality. However, the severity of kidney disease progression and these outcomes differs among patients with various amount of proteinuria. The potential mechanism underlining this disparity may be relevant to the quality and quantity of filtered proteins, especially their mechano-chemical properties such as physical viscosity and stiffness, amino-acid sequence, and molecular weight (low, middle and high molecular weight proteins). The goal of the current project is to develop and validate combined Brillouin & Surface-Enhanced Raman Scattering (SERS) Spectroscopy technique for simultaneous non-contact assessment of visco-elastic and chemical properties of urine proteins as biomarkers of kidney disease. Systematic studies of these properties of proteins in urine samples to be taken from diseased and healthy subjects will be cross-validated by Liquid Chromatography-Mass Spectrometry (LCMS). The project ultimately aims for the development of an optical spectroscopic sensor for rapid, non-contact monitoring of urine samples from patients in clinical settings.

Enrollment: 125 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Both male and female patients with any ethnic group, aged between 18-65 years old
• Newly diagnosed patients with glomerulonephritis and different range of proteinuria

Exclusion criteria

• patients aged <18 and >65 years,
• eGFR<60 ml/min,
• pregnant females,
• patients with diabetes mellitus, cancer, infectious diseases, and other life-treating comorbidities/conditions

Trial design

125 participants in 2 patient groups

Patients with proteinuria

Description:

Patients with newly diagnosed glomerulonephritis with different range of proteinuria at the age between 18-65 years and estimated glomerular filtration rate (GFR) ≥60 ml/min will be included for urine protein measurements

Treatment:

Device: hybrid Brillouin-Raman spectroscopy

Healthy volunteers

Description:

Healthy men/women between age group 18-65 years will be included for urine protein measurements

Treatment:

Device: hybrid Brillouin-Raman spectroscopy